2012
Dr Sandler discovered Hu-PHECs
2013

Hemogenyx Pharmaceuticals founded
2014

Weill Cornell Medicine Daedalus Award

43 North Award
2015
Proof of Principle Studies of Hu-PHEC Umbilical Completed
Hemogenyx Pharmaceuticals LLC obtains exclusive worldwide licence to the Hu-PHEC patent
2016
Patent application filed for CDX antibodies
Proof of Principle studies of CDX antibodies
2017
Patent application filed for of a new type of humanised mice that can be used to advance
product development
product development

Collaboration with the University of Oxford relating to cell therapy

LakePharma appointed as Service Provider for Hemogenyx Pharmaceuticals’ CDX antibody conditioning product
2018
Collaboration with major US biotech company to use Hemogenyx Pharmaceuticals’ humanised mice for drug development and testing
Collaboration with The Rockefeller University to use Hemogenyx Pharmaceuticals’ humanised mice for autoimmune disease modelling
Development agreement with leading global pharmaceutical company for preclinical development of Hemogenyx Pharmaceuticals’ bi-specific CDX antibodies
Collaboration with Janssen Research & Development for the development of a model of lupus using Hemogenyx Pharmaceuticals’ humanised mice
Investments from and collaborations with Orgenesis to further develop Hemogenyx Pharmaceuticals’ Advanced Hematopoietic Chimeras and Hu-PHEC technology
2019
CDX antibody shown to eliminate a subset of ALL cells in vitro and a subset of AML cells in vivo
Development of Advanced peripheral blood Hematopoietic Chimeras, humanised mice without Graft-versus-Host Disease that have additional biodefence applications
New patent application for Hemogenyx Pharmaceuticals’ CDX antibodies for conditioning and composition matter of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells and a number of leukemias
2020
Development of CAR-T therapy product candidate for Acute Myeloid Leukemia
Initiated research into using Hemogenyx Pharmaceuticals’ Advanced Hematopoietic Chimera humanised mice to recreate anti-SARS-CoV-2 virus antibodies to treat COVID-19
Signature of Biological Investigation and Material Supply Agreement with leading global pharmaceutical company for the discovery and validation of materials for the treatment of Lupus and possibly other autoimmune diseases